Prenatal diagnosis of genetic abnormalities:
Has it really moved to the first trimester? OBJECTIVE: Advances in genetic screening can identify patients at high risk for common genetic conditions early in pregnancy, and can facilitate early diagnosis and abortion. Less common abnormalities might only be diagnosed when invasive testing is performed after structural abnormalities are identified. Our objective was to compare gestational ages at diagnosis and abortion for genetic abnormalities identified based on screening and other genetic abnormalities. STUDY DESIGN: All prenatal diagnostic procedures in our department from 2012-2017 were reviewed, and singleton pregnancies terminated following diagnosis of genetic abnormalities were identified. Cases diagnosed as the result of screening tests were compared to remaining cases. Specific conditions were considered "screened for" if they can be suspected by NIPT, biochemistry, carrier screening, or if the patient was a known carrier of a single gene disorder. Since abnormal NT is associated with many genetic disorders, abnormal karyotype, microarray, or Noonan syndrome associated with abnormal NT were considered "screened for". Gestational age at abortion was the primary outcome. Fisher's exact test and MannWhitney U were used for statistical comparison. RESULTS: 267 cases were included. 230 (86%) of abortions were performed for genetic disorders considered screened for, with 209 (91%) of these for karyotype abnormalities, 9 (4%) for microarray abnormalities and 12 (5%) for single gene disorders. 37 (14%) of abortions were performed for conditions not included in screening or with any family history, with 12 (32%) of those for karyotype abnormalities, 18 (49%) for microarray abnormalities and 7 (19%) for single gene disorders. Invasive testing and abortion occurred at earlier median gestational age for those with conditions that were screened for: 12w2d vs. 15w5d; p ¼<.001, and 13w5d vs. 20w0d; p¼<.001. (Table 1 ) CONCLUSION: Most abortions were for common chromosomal abnormalities and single gene disorders that can be suspected early in pregnancy. About 1 in 7 were performed for less common conditions in patients not known to be at risk. Because many structural abnormalities associated with rare genetic conditions will not be identified until the second trimester, prenatal diagnosis and abortion occurred significantly later. Physicians and patients should be aware of the limitations of genetic screening, particularly when restrictions in abortion access can limit options in the second trimester. 
OBJECTIVE:
To assess the frequency of familial versus de novo chromosome inversions during prenatal diagnosis and determine their clinical significance. STUDY DESIGN: A retrospective analysis of prenatally diagnosed inversions from a large reference lab database was performed. The data was reviewed for the type and frequency of various types of inversions, as well as their inheritance pattern. Variant inversion 9 was excluded. RESULTS: A total of 4088 (0.3 %) inversions were identified in a data set of 1.3 million invasive diagnostic procedures. Pericentric inversions accounted for 73% of the inversions (n¼2987), and the remaining 27% were paracentric. Common inversions involving chromosomes 1, 2, 10, and Y accounted for 46.7% of the total inversions (1911/4088). The most frequently identified inversion was inversion 2, inv2(p11q13), accounting for 23% of all inversions. The indications for invasive testing were as follows: advanced maternal age 1941 (47.5%), abnormal aneuploidy screen 935(22.9%), abnormal ultrasound findings 617(15%), previous chromosomal abnormality 449(11%), family history of a significant genetic disorder 69(1.7%), other indication 68(1.7%), and no indication in 10 cases. Excluding the common inversion group, mode of inheritance was available in 81% of cases (1767/2177), with 92% of inversions being inherited (1633/1767). There was a slight preponderance of maternal inheritance (53% , and/or monosomy X), fetal outcomes were solicited randomly for cases that received a high-risk result (defined as 1%). Outcomes were collected by genetic counselors using a standard procedure of up to three requests by telephone, email, and/or facsimile, and verified by medical records when available. Positive predictive values (PPV) were calculated for samples obtained through systematic quality assurance reviews and compared with published performance. RESULTS: During the study period, results were reported for 926,751 cases. A total of 11,808 (1.3%) were high-risk; fetal outcomes were solicited for 3,582 (30.3%) and obtained for 1,579/3,582 (44.1%). Among cases with outcome data, the average maternal and gestational ages were 35.3 years and 13.9 weeks, respectively; average fetal fraction was 11.4%. PPVs were 95.2% (T21), 93.5% (T18), 77.9% (T13), and 86.7% (MX)-consistent with or higher compared with previous published reports 1 (Table 1) . CONCLUSION: This study demonstrates that a laboratory driven, quality assurance program can monitor test performance for noninvasive prenatal screening for aneuploidy. The PPV of NIPT has been the subject of much speculation, however, these data suggest that PPVs are congruent with previous publications and may even be higher than previously reported for T21, T18, T13, and MX.
1 Prospective monitoring of the performance of a laboratory test, or "quality assurance," is the responsibility of a clinical molecular laboratory; the 44.1% follow-up rate for high-risk calls reflects dedication of both laboratory genetic counselors and the obstetrical care providers the laboratory serves. These data demonstrate a successful collaboration between laboratory, genetic counselor, and provider and detail critical information about SNP-based NIPT performance in a general unselected population that, in turn, can enable providers to more accurately counsel patients.
930 Clinical utility of non-invasive prenatal screening for common dominant monogenic disorders 
The discovery of circulating cell-free fetal DNA (ccfDNA) in maternal blood has allowed the development of noninvasive prenatal screening (NIPS) techniques to detect fetal genetic abnormalities. We have developed a 30-gene panel NIPS test for common dominant monogenic disorders with a cumulative incidence comparable to that of common aneuploidies and a similar range of adverse outcomes. We present our clinical experience with this test on >400 pregnancies at moderate to high-risk. STUDY DESIGN: We retrospectively reviewed the test results from 403 plasma samples sent to our laboratory for screening with the singlegene NIPS test. Samples were collected from women with singleton pregnancies with: 1) abnormal fetal ultrasound findings (35.7%, 144/403); 2) family history of relevant or other genetic diseases (8.2%, 33/403); 3) advanced parental age (56.1%, 226/403). Groups 1 and 2 were classified as high-risk, while group 3, advanced maternal age (AMA) 3 35 yr or advanced paternal age (APA) 3 40 yr, was classified as moderate risk. The gestational age (GA) ranged from 9 to 36.6 weeks (average 16.8 weeks). Based on our test clinical sensitivity, specificity, negative predictive value and positive predictive value, a decision-analytic model was used to calculate costs and outcomes for women screened for single gene disorders. Cumulative incidence of the diseases and lifetime costs of an affected child were derived from the literature. RESULTS: Pathogenic or likely pathogenic sequence variants were detected in 18.5% (27/144) of cases with abnormal fetal ultrasound and in 12.1% (4/33) of cases with a positive family history (all four positive cases were with affected fathers). All positive findings were in the high-risk groups (31/177, 17.5%) while no positive findings were detected in the moderate-risk groups. The clinical positive predictive value was >99% in the high-risk population. Using these data to model the detection rate in a theoretical cohort of 4 million women (the total number of pregnancies at 12 weeks GA in the US), support a potential diagnosis of 6,667 affected fetuses (including stillbirth and neonatal death) given a cumulative incidence of these disorders estimated at 1/600. CONCLUSION: Our study supports the clinical utility for our 30-gene panel NIPS test for common dominant monogenic disorders in the high-risk population.
